4878. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
作者: Trong Toan Nguyen.;Cheng-Hsun Chiu.;Chien-Yu Lin.;Nan-Chang Chiu.;Po-Yen Chen.;Thi Tuong Vy Le.;Dang Ngan Le.;An Han Duong.;Van Luan Nguyen.;Thi Nguyet Huynh.;Huu Khanh Truong.;Trong Lan Phan.;Thi Thanh Thao Nguyen.;Shin-Ru Shih.;Chung-Guei Huang.;Yi-Jen Weng.;Erh-Fang Hsieh.;Stanley Chang.;Charles Chen.;I-Chen Tai.;Li-Min Huang.
来源: Lancet. 2022年399卷10336期1708-1717页
Children are susceptible to severe or fatal enterovirus 71 (EV71) infections. We aimed to evaluate the efficacy, safety, and immunogenicity of EV71vac, an aluminium phosphate-adjuvanted inactivated EV71 vaccine in children aged 2-71 months.
|